• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SMARCA4 Gene Record

  • Summary
  • Interactions
  • Claims
  • SMARCA4 6597 Clinically Actionable

    Alternate Names:

    6597
    SWI/SNF RELATED, MATRIX ASSOCIATED, ACTIN DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4
    SMARCA4
    BAF190
    BAF190A
    BRG1
    CSS4
    MRD16
    RTPS2
    SNF2
    SNF2L4
    SNF2LB
    SWI2
    hSNF2b
    603254
    11100
    ENSG00000127616
    OTTHUMG00000169272
    78
    SNF2-beta
    SNF2B

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (5 More Sources)

    Gene Categories: Category Details

    TRANSCRIPTION FACTOR BINDING
    CLINICALLY ACTIONABLE

    Publications:

    Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Xue Y et al., 2019, SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer., Nat Commun
    Xue Y et al., 2019, CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary., Nat Commun
    Italiano A et al., 2018, Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study., Lancet Oncol
    Tagal V et al., 2017, SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers., Nat Commun
  • TAZEMETOSTAT   SMARCA4

    Interaction Score: 3.53

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29650362


    Sources:
    CIViC

  • ABEMACICLIB   SMARCA4

    Interaction Score: 1.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718506 30718512


    Sources:
    CIViC

  • RIBOCICLIB   SMARCA4

    Interaction Score: 1.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718512


    Sources:
    CIViC

  • VINORELBINE   SMARCA4

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26671993


    Sources:
    CIViC

  • PALBOCICLIB   SMARCA4

    Interaction Score: 0.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30718506 30718512


    Sources:
    CIViC

  • TOZASERTIB   SMARCA4

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28102363


    Sources:
    CIViC

  • CISPLATIN   SMARCA4

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26671993


    Sources:
    CIViC

  • Ensembl: ENSG00000127616

    • Version: 101_38

    Alternate Names:
    SMARCA4 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • CIViC: SMARCA4

    • Version: 14-September-2020

    Alternate Names:
    6597 Entrez Gene ID
    78 CIViC Gene ID

    Gene Info:

    Publications:
    Tagal V et al., 2017, SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers., Nat Commun
    Bell et al., 2016, SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Italiano A et al., 2018, Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study., Lancet Oncol

  • NCI: SMARCA4

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Sumi-Ichinose et al., 1997, SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells., Mol. Cell. Biol.

  • GO: SMARCA4

    • Version: 01-February-2022

    Alternate Names:
    BAF190A GO Gene Synonym
    BRG1 GO Gene Synonym
    SNF2B GO Gene Synonym

    Gene Info:

    Gene Categories:
    TRANSCRIPTION FACTOR BINDING

    Publications:

  • Tempus: SMARCA4

    • Version: 11-November-2018

    Alternate Names:
    SMARCA4 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MskImpact: SMARCA4

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FoundationOneGenes: SMARCA4

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: SMARCA4

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: SMARCA4

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21